ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
When it comes to developing new pharmaceuticals, the molecular structure of a compound isn’t drugmakers’ only concern. Scientists at Merck & Co. Inc. in Rahway, N.J., are researching these crystals, which were made by crystallizing the same small-molecule drug candidate yet have noticeably different shapes, or crystal habits. The two habits are a result of the solvent used during crystallization: Isopropyl alcohol yields the rhombic platelets (left) while a mixture of ethyl acetate and toluene yield hexagonal ones (right). Pharma companies want to control crystal habits because a crystal’s shape can affect how well the drug dissolves, how stable the drug is in suspensions, and how easily it can be processed while being synthesized.
Submitted by Billy Chen, Luke Schenck, Zhiwei Yin, and Alfred Y. Lee
Do science. Take pictures. Win money. Enter our photo contest here.
Related C&EN Content:
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X